Brand-Boosting Schiff Nutrition Sees Upside In Top-Selling Supplements
This article was originally published in The Tan Sheet
Schiff Nutrition CEO Tarang Amin, a veteran of managing brands for Clorox and P&G, sees additional upside in top-selling brands such as MegaRed and Move Free. The firm also is de-emphasizing its struggling private label business.
You may also be interested in...
The $150 million price represents more than twice Airborne’s approximately $70 million in annual net revenues for supplements marketed to strengthen immune support. The acquisition from GF Capital follows Pfizer’s recent foray into the immune support space by buying the maker of Emergen-C products.
Private label giant Perrigo is readying generic competitors to Reckitt Benckiser’s Mucinex and Takeda Pharmaceuticals’ Prevacid, CEO Joseph Papa says.
Schiff Nutrition International makes a $40 million investment in probiotic supplements by acquiring worldwide exclusive rights to the GanedenBC30 strain and a pair of consumer probiotics brands.